[8-K] Contineum Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. furnished an 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.

The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act, and will not be incorporated by reference into any Securities Act registration statement unless specifically identified.

false 0001855175 0001855175 2025-10-30 2025-10-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2025

Contineum Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42001		27-1467257
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3565 General Atomics Court, Suite 200 San Diego, California		92121
(Address of principal executive offices)		(Zip Code)

(858) 333-5280

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.001 per share		CTNM		The Nasdaq Global Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company          ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02 Results of Operations and Financial Condition.

On October 30, 2025, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)  Exhibits.

Exhibit No.		Description
99.1		Press release dated October 30, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 30, 2025

Contineum Therapeutics, Inc.
By:		/s/ Peter Slover
		Peter Slover
		Chief Financial Officer Principal Financial Officer and Principal Accounting Officer

FAQ

What did CTNM announce in this 8-K?

Contineum Therapeutics furnished a press release with its financial results for the third quarter ended September 30, 2025, included as Exhibit 99.1.

Is the Q3 2025 press release considered filed or furnished?

It is furnished under Item 2.02 and is not deemed “filed” for Section 18 of the Exchange Act.

Will the press release be incorporated by reference?

It will not be incorporated by reference into any Securities Act registration statement unless specifically identified as such.

Which exhibit contains the press release for CTNM?

The press release is provided as Exhibit 99.1.

What period do the announced results cover for CTNM (CTNM)?

They cover the third quarter ended September 30, 2025.

What Exchange Act item applies to this disclosure for CTNM?

The disclosure is under Item 2.02 (Results of Operations and Financial Condition).